Hedenstedt, Anna, Reid, Sarah, Sayadi, Ahmed, Eloranta, Maija-Leena, Skoglund, Elisabeth, Bolin, Karin, Frodlund, Martina, Lerang, Karoline, Joensen, Andreas, Rantapaeae-Dahlqvist, Solbritt, Bengtsson, Anders A., Rudin, Anna, Molberg, Oyvind, Sjoewall, Christopher, Sandling, Johanna K., Leonard, Dag, Hedenstedt, Anna, Reid, Sarah, Sayadi, Ahmed, Eloranta, Maija-Leena, Skoglund, Elisabeth, Bolin, Karin, Frodlund, Martina, Lerang, Karoline, Joensen, Andreas, Rantapaeae-Dahlqvist, Solbritt, Bengtsson, Anders A., Rudin, Anna, Molberg, Oyvind, Sjoewall, Christopher, Sandling, Johanna K., and Leonard, Dag
Objective: B cell function and autoantibodies are important in SLE pathogenesis. In this work, we aimed to investigate the impact of cumulative SLE B cell genetics on SLE subphenotype and autoantibody profile. Methods: Female patients with SLE (n=1248) and healthy controls (n=400) were genotyped using Illumina's Global Screening Array. Two polygenic risk scores (PRSs), one representing B cell genes and the other B cell activation genes, were calculated for each individual using risk loci for SLE in genes assigned to B cell-related pathways according to the Kyoto Encyclopedia of Genes and Genomes, Gene Ontology and Reactome Databases. Results: Double-stranded DNA (dsDNA) antibodies were more prevalent among patients with a high compared with a low SLE B cell PRS (OR 1.47 (1.07 to 2.01), p=0.018), and effect sizes were augmented in patients with human leucocyte antigen (HLA) risk haplotypes HLA-DRB1*03:01 and HLA-DRB1*15:01 (DRB1*03/15 -/- (OR 0.99 (0.56 to 1.77), p=0.98; DRB1*03/15 +/- or -/+ (OR 1.64 (1.06 to 2.54), p=0.028; and DRB1*03/15 +/+ (OR 4.47 (1.21 to 16.47), p=0.024). Further, a high compared with a low B cell PRS was associated with low complement levels in DRB1*03/15 +/+ patients (OR 3.92 (1.22 to 12.64), p=0.022). The prevalence of lupus nephritis (LN) was higher in patients with a B cell activation PRS above the third quartile compared with patients below (OR 1.32 (1.00 to 1.74), p=0.048). Conclusions: High genetic burden related to B cell function is associated with dsDNA antibody development and LN. Assessing B cell PRSs may be important in order to determine immunological pathways influencing SLE and to predict clinical phenotype.